INS and chronic kidney disease: Due to the extensive metabolic regulatory impact of insulin, T2DM patients usually present a range of metabolic disorders, including aberrant metabolism of glucose, lipid, protein, and electrolyte, etc. Among these metabolic disorders, dyslipidemias with the prevalence as high as 75% contributes significantly to the elevated risk of cardiovascular disease including chronic kidney disease (CKD) [3].